Description

Product Description

Invopressin (CAS 1488411-60-4), also known as Compound 42, is a synthetic small molecule that functions as a selective vasopressin V1A receptor partial agonist. With an EC50 of approximately 1.0 nM, Invopressin demonstrates potent receptor engagement while maintaining a partial activation profile, making it highly suitable for research into hepatic and renal complications associated with cirrhosis.

Background

Vasopressin, also known as antidiuretic hormone (ADH), is a key regulator of vascular tone, renal function, and fluid homeostasis. It exerts its biological effects through V1A, V1B, and V2 receptor subtypes. Among these, V1A receptors are primarily expressed in vascular smooth muscle and hepatosplanchnic circulation, mediating vasoconstriction and contributing to hemodynamic regulation.

Cirrhosis is often accompanied by portal hypertension, ascites, bacterial peritonitis, and hepatorenal syndrome type 2 (HRS2). These complications are partly driven by profound splanchnic vasodilation, systemic hypotension, and impaired renal perfusion. By selectively modulating V1A receptors, Invopressin provides a unique pharmacological tool to investigate therapeutic approaches for these pathophysiological states.

Research Value

Unlike full V1A agonists, Invopressin’s partial agonist profile allows researchers to dissect the nuanced role of receptor modulation without inducing excessive vasoconstriction or off-target effects. This makes it particularly valuable for:

• Cirrhosis research: Understanding splanchnic hemodynamics and compensatory mechanisms.

• Bacterial peritonitis studies: Modeling immune, vascular, and renal interactions during infection-related decompensation.

• HRS2 models: Exploring reno-hepatic cross-talk in chronic liver failure.

• Refractory ascites research: Investigating how controlled vasoconstriction influences fluid accumulation and diuresis.

Advantages Over Conventional Vasopressin Analogs

• Partial agonism: Avoids excessive vasoconstriction seen with full agonists.

• Selectivity: Strong preference for V1A receptors, reducing off-target V2 receptor effects.

• Reproducibility: GMP-grade synthesis ensures batch consistency.

• Versatility: Applicable in rodent, large-animal, and in vitro models.

By offering a reliable and well-characterized compound, Invopressin enables mechanistic and translational studies into cirrhosis management strategies and hemodynamic regulation.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Invopressin binds selectively to V1A receptors located on vascular smooth muscle, initiating partial agonist activity. This engagement results in:

1. Controlled Vasoconstriction

   • Induces moderate splanchnic vasoconstriction.

   • Restores effective arterial blood volume.

2. Improved Renal Perfusion

   • Counteracts vasodilation-induced hypoperfusion in cirrhotic models.

   • Supports renal hemodynamics in HRS2 studies.

3. Reduced Portal Hypertension

   • Lowers splanchnic blood flow, thereby modulating portal venous pressure.

4. Partial Agonism Benefits

   • Limits excessive systemic vasoconstriction.

   • Balances efficacy and safety in preclinical experiments.

     

Research Applications

• Cirrhosis & Portal Hypertension
  Study vascular tone, portal flow, and systemic hemodynamics in animal models of cirrhosis.

• Bacterial Peritonitis
  Investigate host responses, cytokine release, and hemodynamic regulation in infectious complications.

• Hepatorenal Syndrome Type 2 (HRS2)
  Evaluate how partial agonism influences renal function, glomerular filtration, and sodium handling.

• Refractory Ascites
  Test fluid balance and diuretic responsiveness under controlled V1A activation.

• Comparative Pharmacology
  Benchmark Invopressin against full agonists like terlipressin and vasopressin analogs.

• Translational Research
  Provide insights into novel therapeutic strategies for cirrhosis-related decompensation.

Side Effects (For Research Reference)

Experimental observations with Invopressin in preclinical studies include:

• Hemodynamic Effects: Moderate increases in blood pressure and systemic vascular resistance.

• Renal Responses: Altered urine output and sodium excretion depending on dose.

• Gastrointestinal Effects: Possible reduced blood flow to intestines during high-dose exposure.

• Species-Specific Variability: Different vascular responses observed in rodent vs. primate models.

• Tachyphylaxis Risk: Repeated dosing may reduce responsiveness over time.

• Injection Site Reactions: Local irritation in subcutaneous models.

These findings are strictly experimental. Invopressin is not for human or veterinary use.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Invopressin

• Invopressin CAS 1488411-60-4

• Compound 42 vasopressin analog

• V1A receptor partial agonist peptide

• Cirrhosis research compound

• Ascites pharmacology research

• GMP supplier Invopressin

• Hepatorenal syndrome research peptide

• Bacterial peritonitis research tool

• Laboratory hemodynamics research peptide